benzyl(methyl)[(2R)-1-phenylpropan-2-yl]amine | 26097-55-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl(methyl)[(2R)-1-phenylpropan-2-yl]amine
• 英文别名: benzyl-methyl-((R)-1-methyl-2-phenyl-ethyl)-amine；Benzyl-methyl-((R)-1-methyl-2-phenyl-aethyl)-amin；(R)-Benzphetamine；(2R)-N-benzyl-N-methyl-1-phenylpropan-2-amine
• CAS: 26097-55-2
• 化学式: C₁₇H₂₁N
• 分子量: 239.36
• InChiKey: YXKTVDFXDRQTKV-OAHLLOKOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

ADMET

代谢

Zinc968306已知的人类代谢物包括1-苯基-2-苄基氨基丙烷。

Zinc968306 has known human metabolites that include 1-Phenyl-2-benzylaminopropane.

来源:NORMAN Suspect List Exchange

反应信息

• 作为产物：
  描述：

  左旋甲基苯丙胺 、 氯化苄 生成 benzyl(methyl)[(2R)-1-phenylpropan-2-yl]amine
  参考文献：
  名称：

  Physiologically Active Amines. Tertiary Amines and Quaternary Salts Related to β-(o-Methoxyphenyl)-isopropyl-N-methylamine

  摘要：

  DOI：

  10.1021/ja01100a044

文献信息

• AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS
  申请人：CHEMAPOTHECA, LLC

  公开号：US20180243241A1

  公开（公告）日：2018-08-30

  The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

  这项发明还涉及包含高纯度苯丙胺和苯丙胺类化合物的药物组合物，这些化合物是通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成而得到的，并且涉及通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成而得到的苯丙胺化合物的制造、输送和使用方法。
• [EN] AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE DETERRENT DOSAGE FORMS<br/>[FR] LIBÉRATION CONTRÔLÉE DE L'AMPHÉTAMINE, PROMÉDICAMENT ET FORMES POSOLOGIQUES DISSUASIVES DU MÉSUSAGE
  申请人：CHEMAPOTHECA LLC

  公开号：WO2017147375A1

  公开（公告）日：2017-08-31

  The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

  这项发明还涉及包含高纯度苯丙胺和苯丙胺类化合物的药物组合物，这些化合物是通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成的，以及通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成的苯丙胺化合物的制造、输送和使用方法。
• Methods of Treatment Using Amphetamine Controlled Release, Prodrug, and Abuse Deterrent Dosage Forms
  申请人：CHEMAPOTHECA, LLC

  公开号：US20210030699A1

  公开（公告）日：2021-02-04

  The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

  本发明还涉及制备高纯度苯丙胺及苯丙胺类化合物的药物组合物，该组合物是通过使用手性和消旋苯丙胺衍生物合成，利用具有立体选择性和区域选择性的杯酸铜加成反应与环氧乙烷磷酰胺化合物反应所得到的。本发明还涉及制备、传递和使用通过使用手性和消旋苯丙胺衍生物合成，利用具有立体选择性和区域选择性的杯酸铜加成反应与环氧乙烷磷酰胺化合物反应所得到的苯丙胺类化合物的方法。
• Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms
  申请人：CHEMAPOTHECA, LLC

  公开号：US11123310B2

  公开（公告）日：2021-09-21

  The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

  本发明还涉及药物组合物，其中包含通过与氮丙啶磷酰胺化合物的立体特异性、区域选择性杯突加成反应合成手性和外消旋安非他明衍生物所得到的高纯度安非他明和安非他明类化合物，以及通过与氮丙啶磷酰胺化合物的立体特异性、区域选择性杯突加成反应合成手性和外消旋安非他明衍生物所得到的安非他明化合物的制造、交付和使用方法。
• AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE DETERRENT DOSAGE FORMS
  申请人：Chemapotheca LLC

  公开号：EP3478363A1

  公开（公告）日：2019-05-08